Peerview Neuroscience & Psychiatry Cme/cne/cpe Audio Podcast

Sinopse

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episódios

  • Diana Castro, MD - Great Expectations: Helping Patients With Spinal Muscular Atrophy and Their Families Understand Diagnosis and Treatment in a New Era of Therapy

    Diana Castro, MD - Great Expectations: Helping Patients With Spinal Muscular Atrophy and Their Families Understand Diagnosis and Treatment in a New Era of Therapy

    26/08/2020 Duração: 36min

    Go online to PeerView.com/HWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the diagnosis and treatment of spinal muscular atrophy in a new era of therapy. Upon completion of this activity, participants should be better able to: Employ current recommendations for screening and diagnosis of patients suspected to have spinal muscular atrophy (SMA), Recognize clinical signs and symptoms associated with early manifestations of SMA from birth to adulthood, Apply current data on the efficacy, safety, and tolerability of approved disease-modifying therapies for SMA from infancy through adulthood, Counsel patients and/or their parents/caregivers regarding the need for ongoing supportive care to optimize treatment outcomes.

  • Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    13/05/2020 Duração: 51min

    Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms o

  • Brenda L. Banwell, MD, FAAP, FRCPC, FAAN - Addressing Barriers to the Ready Recognition and Timely Treatment of Pediatric Multiple Sclerosis

    "Brenda L. Banwell, MD, FAAP, FRCPC, FAAN - Addressing Barriers to the Ready Recognition and Timely Treatment of Pediatric Multiple Sclerosis"

    25/03/2020 Duração: 32min

    Go online to PeerView.com/DKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multiple sclerosis expert discusses diagnosing, treating, and managing pediatric-onset multiple sclerosis. Upon completion of this activity, participants should be better able to: Identify patients with pediatric-onset multiple sclerosis according to their presenting symptoms and established criteria, Assess available data on approved disease-modifying therapies for the treatment of pediatric-onset multiple sclerosis, Select an appropriate course of disease-modifying therapy in individuals with pediatric- onset multiple sclerosis

  • Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    24/01/2020 Duração: 25min

    Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy

  • Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    22/01/2020 Duração: 11min

    Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis

  • Steven Brem, MD - Brainstorming Personalized Care Strategies in Glioblastoma: Rethinking and Refining Therapeutic Algorithms With Tumor Treating Fields and Novel Systemic Approaches

    Steven Brem, MD - Brainstorming Personalized Care Strategies in Glioblastoma: Rethinking and Refining Therapeutic Algorithms With Tumor Treating Fields and Novel Systemic Approaches

    15/01/2020 Duração: 54min

    Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug cl

  • Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence  Clinical Application Across a Range of Solid Malignancies

    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    13/12/2019 Duração: 01h19min

    Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management.

  • Joshua D. Lee, MD, MSc - Caring for the Patient With Opioid Use Disorder in an Outpatient Setting: Overcoming the Barriers to Medication-Assisted Treatment

    Joshua D. Lee, MD, MSc - Caring for the Patient With Opioid Use Disorder in an Outpatient Setting: Overcoming the Barriers to Medication-Assisted Treatment

    15/11/2019 Duração: 40min

    Go online to PeerView.com/XXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in addiction medicine discusses opioid use disorder in the outpatient setting and overcoming the various barriers to patients receiving medication. Upon completion of this activity, participants should be better able to: Identify barriers to the implementation of medication-assisted treatment (MAT) for patients with opioid use disorder (OUD), Discuss the efficacy of treatment programs that include MAT for the management of OUD, Employ strategies to effectively and safely integrate MAT into the management of patients with OUD, to reduce opioid misuse and improve treatment retention, particularly in the outpatient setting

  • Joseph I. Sirven, MD - Generalized Tonic-Clonic Seizures: Clinical Pearls for Recognition and Optimal Management

    Joseph I. Sirven, MD - Generalized Tonic-Clonic Seizures: Clinical Pearls for Recognition and Optimal Management

    11/10/2019 Duração: 25min

    Go online to PeerView.com/PDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the diagnosis and management of patients with generalized tonic-clonic seizures. Upon completion of this activity, participants should be better able to: Differentiate generalized tonic-clonic seizures from other seizure types in patients with epilepsy, Recognize the significance of early antiepileptic drug treatment in patients with generalized tonic-clonic seizures, Cite current data on the efficacy and safety of approved therapies for the treatment of generalized tonic-clonic seizures, Apply available adjunctive strategies to manage treatment-resistance in patients with generalized tonic-clonic seizures

  • Michael Polydefkis, MD - Clinical Pearls for the Accurate Diagnosis and Optimal Treatment of Hereditary ATTR Amyloidosis

    Michael Polydefkis, MD - Clinical Pearls for the Accurate Diagnosis and Optimal Treatment of Hereditary ATTR Amyloidosis

    31/07/2019 Duração: 21min

    Go online to PeerView.com/HMV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert neurologist shares clinical pearls for accurately diagnosing and optimally treating patients with hereditary ATTR amyloidosis. Upon completion of this activity, participants should be better able to: Describe the common symptoms and underlying genetic mechanisms of hereditary ATTR amyloidosis, Apply genetic testing methods to accurately diagnose hereditary ATTR amyloidosis, Cite recent efficacy and safety data about available therapies for the management of hereditary ATTR amyloidosis, Employ approved therapies to reduce hospitalizations and mortality in patients with hereditary ATTR amyloidosis.

  • Bruce Cree, MD, PhD, MAS - Examining Late-Breaking Data on Disease-Modifying Therapies for the Treatment of Multiple Sclerosis — An Update From Philadelphia

    Bruce Cree, MD, PhD, MAS - Examining Late-Breaking Data on Disease-Modifying Therapies for the Treatment of Multiple Sclerosis — An Update From Philadelphia

    29/07/2019 Duração: 33min

    Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

  • Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

    Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

    17/07/2019 Duração: 49min

    Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of mul

  • Adam Boxer, MD - Progressive Supranuclear Palsy: Examining Diagnostic Considerations and Emerging Treatment Approaches

    Adam Boxer, MD - Progressive Supranuclear Palsy: Examining Diagnostic Considerations and Emerging Treatment Approaches

    08/07/2019 Duração: 27min

    Go online to PeerView.com/YPK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the symptoms, diagnosis, and management of patients with progressive supranuclear palsy, focusing on pathophysiology, detection, and therapeutic approaches currently under investigation. Upon completion of this activity, participants should be better able to: Identify patients with progressive supranuclear palsy based on their presentation, symptoms, and laboratory test results, Assess the potential benefits and clinical shortcomings of current symptomatic and supportive care approaches for patients with progressive supranuclear palsy, Cite available data and ongoing trials on emerging tau-targeted therapies for the treatment of progressive supranuclear palsy, Recognize the potential impact of emerging tau-targeted therapies on the future management of progressive supranuclear palsy.

  • Jerry Vockley, MD, PhD - Diminishing the Burden of Phenylketonuria During Adulthood: New Science  Encouraging Stories Highlighting the Critical Role of Adjunctive Therapy in Alleviating Neurocognitive Symptoms and Easing Dietary Constraints

    Jerry Vockley, MD, PhD - Diminishing the Burden of Phenylketonuria During Adulthood: New Science & Encouraging Stories Highlighting the Critical Role of Adjunctive Therapy in Alleviating Neurocognitive Symptoms and Easing Dietary Constraints

    14/06/2019 Duração: 54min

    Go online to PeerView.com/UGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.In this activity, experts in PKU discuss available adjunctive treatments, which provide an opportunity to lower blood Phe levels while potentially easing dietary restrictions and lessening the burden of this disease. Upon completion of this activity, participants should be better able to: Employ current practice guidelines and standards of care when managing individuals with phenylketonuria (PKU), Identify the challenges associated with dietary therapy in patients with PKU as they transition from childhood to adolescence and into adulthood, Describe the mechanisms of action of available adjunctive treatment approaches for the management of PKU, Assess available data on the efficacy, safety, and tolerability of approved adjunctive pharmacologic therapies for the management of adults with PKU, Apply available adjunctive therapies as part of a personalized approach to the management

  • Kevin N. Sheth, MD - Exploring Unmet Needs in Large Hemispheric Infarction: Clinical Insights on Early Recognition and Emerging Therapy

    Kevin N. Sheth, MD - Exploring Unmet Needs in Large Hemispheric Infarction: Clinical Insights on Early Recognition and Emerging Therapy

    02/06/2019 Duração: 29min

    Go online to PeerView.com/AKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses current and emerging interventions to reduce morbidity and mortality due to cerebral edema in patients with LHI. Upon completion of this activity, participants should be better able to: Apply evidence-based strategies for evaluation and management of large hemispheric infarction (LHI), Recognize the latest clinical trial data evaluating emerging therapy in the management of LHI and how this data applies to current practice

  • Stewart J. Tepper, MD, FAHS - Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention

    Stewart J. Tepper, MD, FAHS - Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention

    26/04/2019 Duração: 53min

    Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical

  • Anup D. Patel, MD, FAAN - Harnessing the Full Potential of Available Therapies for the Treatment of Lennox-Gastaut Syndrome: A Story Behind the Science

    Anup D. Patel, MD, FAAN - Harnessing the Full Potential of Available Therapies for the Treatment of Lennox-Gastaut Syndrome: A Story Behind the Science

    08/04/2019 Duração: 26min

    Go online to PeerView.com/XYB860 to view the entire program with slides. In this activity, an expert in the management of Lennox-Gastaut syndrome discusses the challenges of identifying, diagnosing, and treating patients with this condition. Upon completion of this activity, participants should be better able to: Identify patients with Lennox-Gastaut syndrome based on the presence of cardinal symptoms and hallmark features, Cite current data on approved pharmacologic therapies for the treatment of seizures associated with Lennox-Gastaut syndrome, Develop personalized seizure management regimens for patients with Lennox-Gastaut syndrome.

  • Aaron Boster, MD - Improving Outcomes in Multiple Sclerosis Through the Practice of Shared Decision-Making in Disease-Modifying Therapy Selection

    Aaron Boster, MD - Improving Outcomes in Multiple Sclerosis Through the Practice of Shared Decision-Making in Disease-Modifying Therapy Selection

    13/03/2019 Duração: 22min

    Go online to PeerView.com/PPP860 to view the entire program with slides. In this activity, an expert in multiple sclerosis discusses available disease-modifying therapies and strategies for shared decision-making for patients with multiple sclerosis. Upon completion of this activity, participants should be better able to: Recognize the mechanisms of action of disease-modifying therapeutic options for patients with multiple sclerosis, Apply available data on disease-modifying therapies when managing patients with multiple sclerosis, Employ evidence-based strategies designed to facilitate shared decision-making and maintain a therapeutic alliance with patients with multiple sclerosis.

  • Marwan Sabbagh, MD, FAAN - Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?

    Marwan Sabbagh, MD, FAAN - Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?

    19/02/2019 Duração: 45min

    Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?

  • Barry Singer, MD - Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

    Barry Singer, MD - Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

    23/01/2019 Duração: 43min

    Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

página 1 de 2

Informações: